BIOGEN INC. Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One
BIOGEN INC. (BIIB) had Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One of $900.80 million as of 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Notes › Debt and Equity Securities › Available-for-Sale Securities, Debt Maturities › Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost · last filed 2026-04-29
- 2026-03-31: Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One $900.80M.
- 2025-12-31: Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One $807.20M.
- 2025-09-30: Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One $97.60M.
- 2023-06-30: Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One $3.47B.
| Period end | Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One |
|---|---|
| 2026-03-31 | $900.80M 10-Q · filed 2026-04-29 |
| 2025-12-31 | $807.20M 10-Q · filed 2026-04-29 |
| 2025-09-30 | $97.60M 10-Q · filed 2025-10-30 |
| 2023-06-30 | $3.47B 10-Q · filed 2023-07-25 |
| 2023-03-31 | $2.15B 10-Q · filed 2023-04-25 |
| 2022-12-31 | $1.48B 10-K · filed 2024-02-14 |
| 2022-09-30 | $1.24B 10-Q · filed 2022-10-25 |
| 2022-06-30 | $2.15B 10-Q · filed 2022-07-20 |
| 2022-03-31 | $2.00B 10-Q · filed 2022-05-03 |
| 2021-12-31 | $1.54B 10-K · filed 2023-02-15 |
| 2021-09-30 | $1.41B 10-Q · filed 2021-10-20 |
| 2021-06-30 | $1.31B 10-Q · filed 2021-07-22 |
| 2021-03-31 | $1.32B 10-Q · filed 2021-04-22 |
| 2020-12-31 | $1.28B 10-K · filed 2022-02-03 |
| 2020-09-30 | $1.35B 10-Q · filed 2020-10-21 |
| 2020-06-30 | $1.94B 10-Q · filed 2020-07-22 |
| 2020-03-31 | $1.27B 10-Q · filed 2020-04-23 |
| 2019-12-31 | $1.56B 10-K · filed 2021-02-03 |
| 2019-09-30 | $2.09B 10-Q · filed 2019-10-22 |
| 2019-06-30 | $1.23B 10-Q · filed 2019-07-24 |
| 2019-03-31 | $1.67B 10-Q · filed 2019-04-24 |
| 2018-12-31 | $2.31B 10-K · filed 2020-02-06 |
| 2018-09-30 | $2.04B 10-Q · filed 2018-10-23 |
| 2018-06-30 | $1.97B 10-Q · filed 2018-07-24 |
| 2018-03-31 | $1.81B 10-Q · filed 2018-04-24 |
| 2017-12-31 | $2.12B 10-K · filed 2019-02-06 |
| 2017-09-30 | $1.96B 10-Q · filed 2017-10-24 |
| 2017-06-30 | $1.72B 10-Q · filed 2017-07-25 |
| 2017-03-31 | $1.96B 10-Q · filed 2017-04-25 |
| 2016-12-31 | $2.57B 10-K · filed 2018-02-01 |
| 2016-09-30 | $2.23B 10-Q · filed 2016-10-26 |
| 2016-06-30 | $2.43B 10-Q · filed 2016-07-21 |
| 2016-03-31 | $2.45B 10-Q · filed 2016-04-21 |
| 2015-12-31 | $2.12B 10-K · filed 2017-02-02 |
| 2015-09-30 | $1.75B 10-Q · filed 2015-10-21 |
| 2015-06-30 | $1.09B 10-Q · filed 2015-07-24 |
| 2015-03-31 | $674.00M 10-Q · filed 2015-04-24 |
| 2014-12-31 | $640.80M 10-K · filed 2016-02-03 |
| 2014-09-30 | $675.00M 10-Q · filed 2014-10-22 |
| 2014-06-30 | $709.80M 10-Q · filed 2014-07-23 |
| 2014-03-31 | $431.50M 10-Q · filed 2014-04-23 |
| 2013-12-31 | $620.20M 10-K · filed 2015-02-04 |
| 2013-09-30 | $240.90M 10-Q · filed 2013-10-28 |
| 2013-06-30 | $275.30M 10-Q · filed 2013-07-25 |
| 2013-03-31 | $0.00 10-Q · filed 2013-04-25 |
| 2012-12-31 | $1.13B 10-K · filed 2014-02-06 |
| 2012-09-30 | $1.15B 10-Q · filed 2012-10-25 |
| 2012-06-30 | $948.70M 10-Q · filed 2012-07-24 |
| 2012-03-31 | $978.00M 10-Q · filed 2012-05-01 |
| 2011-12-31 | $1.18B 10-K · filed 2013-02-05 |
| 2011-09-30 | $944.10M 10-Q · filed 2011-10-28 |
| 2011-06-30 | $628.70M 10-Q · filed 2011-07-26 |
| 2011-03-31 | $437.40M 10-Q · filed 2011-04-21 |
| 2010-12-31 | $447.80M 10-K · filed 2012-02-03 |
| 2010-09-30 | $167.90M 10-Q · filed 2010-10-26 |
| 2010-06-30 | $204.80M 10-Q · filed 2010-07-20 |
| 2009-12-31 | $519.50M 10-K · filed 2011-02-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |